Carregant...
When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat Shock Response
Multiple myeloma (MM) is a plasma cell malignancy with an estimated 26,850 new cases and 11,240 deaths in 2015 in the United States. Two main classes of agents are the mainstays of therapy - proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs). Other new targets are emerging rapidly, inclu...
Guardat en:
| Publicat a: | Mol Cancer Res |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4874259/ https://ncbi.nlm.nih.gov/pubmed/26013169 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-15-0135 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|